此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

C Reactive Protein (CRP) Intervention to Reduce Inappropriate Antibiotic Prescriptions in the Primary Healthcare Setting (CRP)

Efficacy of Point-of-care (POC) C-reactive Protein Testing to Reduce Inappropriate Use of Antibiotics for Acute Respiratory Infections (ARIs) in the Primary Health Care Setting of Hanoi - a Randomized Controlled Trial

Many studies have showed that rapid point-of-care (POC) c-reactive protein (CRP) test can reduce inappropriate use of antibiotic at primary health care level. In Vietnam, prevalence of antibiotic abuse for community acute respiratory infection has been reported. This study will test the hypothesis that CRP POC testing for patients with non-severe acute respiratory illness at primary healthcare stations reduces inappropriate antibiotic use safely.

The study will be conducted at ten district health care facilities in Hanoi, Viet Nam. Investigators intend to enroll 2,000 participants aged 6-65 years with non-severe acute respiratory infection. Patients will be randomly allocated to the control or the intervention arm. Participants in the control group will be treated according to routine care. Participants in the intervention arm will have a CRP test, the results of which will be available to the health care practitioner to contribute to their diagnosis and treatment decisions.

All patients will be followed-up via telephone call after 14 days. The study will compare the proportion of patients in each arm receiving any antibiotics within 2 weeks of study enrollment.

研究概览

研究类型

介入性

注册 (实际的)

2037

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Hanoi、越南、10000
        • National Hospital for Tropical Diseases

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 至 65年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients, aged 6 to 65 years, that visit one of the 10 selected primary healthcare centers
  • Suspected to have acute respiratory tract infection (ARI) by treating physician
  • Informed consent

Exclusion Criteria:

  • Severe respiratory disease as determined by treating doctor
  • Any disease or symptom requiring hospital referral as determined by treating doctor
  • Immunosuppressed patients (e.g. HIV, long term steroid use)
  • Suspicion of tuberculosis
  • Evidence of acute or chronic liver disease (e.g. hepatitis or cirrhosis due to any cause)
  • Past medical history of: neoplastic disease, congestive cardiac failure, chronic obstructive pulmonary disease, insulin-dependent diabetes or renal disease
  • Pregnancy
  • No access to telephone
  • Not able to come for follow up visit on day 3 or 4.
  • Already taking antibiotics at the time of presentation
  • Symptoms present for more than 2 weeks
  • Presence of any sign of severe diseases as defined by the British Thoracic Society modified CRP-65 system for severity scoring of pneumonia in primary care.

For children (Age ≥ 6 years and < 16 years) additional exclusion criteria include: Tachypnea, signs of chest wall in drawing, reduced consciousness, confusion, dehydration, hypothermia, severe malnutrition, unable to feed or drink, vomiting, and convulsions.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:CRP intervention
Patients will be tested by rapid POC CRP test
Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
无干预:Control
Patients will not be tested by rapid POC CRP test

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of patients receiving any antibiotic
大体时间:2 weeks
Number of patients receiving any antibiotic within 2 weeks of study enrollment as a proportion of the total number of patients.
2 weeks

次要结果测量

结果测量
措施说明
大体时间
Duration of symptoms
大体时间:2 weeks
Number of days that symptoms (including fever or any respiratory symptom) endure.
2 weeks
Frequency of re-consultation
大体时间:2 weeks
Number of visits to a health care practitioner during the 14 day follow-up.
2 weeks
Frequency of serious adverse events
大体时间:2 weeks
Number of serious adverse events which occur during the 14 day follow-up period.
2 weeks

其他结果措施

结果测量
措施说明
大体时间
The attitudes and satisfaction of patients and health center staff towards the test.
大体时间:2 weeks

Patients and health center staff will be interviewed by structured questionnaire to assess their attitudes and satisfaction toward the intervention.

The Likert scale will be used for quantifying attitude orientation of interviewees

2 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Heiman FL Wertheim, M.D,Ph.D、Oxford University Clinical Research Unit

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年3月1日

初级完成 (实际的)

2015年7月1日

研究完成 (实际的)

2015年9月1日

研究注册日期

首次提交

2013年8月6日

首先提交符合 QC 标准的

2013年8月6日

首次发布 (估计)

2013年8月7日

研究记录更新

最后更新发布 (估计)

2016年11月15日

上次提交的符合 QC 标准的更新

2016年11月13日

最后验证

2014年6月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 05HN

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅